Skip to main content
. 2023 Mar 15;12(6):908. doi: 10.3390/cells12060908

Figure 2.

Figure 2

Repeated ICV delivery of tcDNA and PMO. (A) Quantification by fluorescent hybridization assay of tcDNA-Ex51 content in various CNS tissues after three multiple injections via a cannula implant 4 weeks after tcDNA administration. Results are expressed as means ± SEMs; n = 3 mdx52-tcDNA-Ex51 in cannula groups. (B) Quantification of exon 51-skipping levels via RT-qPCR in different brain tissues. Results are expressed as means ± SEMs; n = 3 mdx52-tcDNA-Ex51 in cannula groups. (C) Quantification of exon 51-skipping levels via RT-qPCR in different brain tissues 7 weeks after either single ICV slow-bolus injection or three administrations via a cannula implant of PMO. (D) Quantification of exon 51-skipping levels via RT-qPCR in different brain tissues after very slow diffusion via osmotic pumps of tcDNA. CBL: cerebellum, CX: cortex, HIPPO: hippocampus, and SC: spinal cord (cervical region). Results are expressed as means ± SEMs; n = 3 mdx52-minipump-tcDNA-Ex51.